Get the Stockscreener App
220.89
0.70%
-1.55
After Hours:
220.68
-0.21
-0.10%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $220.89, with a volume of 8.07M.
It is down -0.70% in the last 24 hours and up +0.37% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$222.44
Open:
$222.27
24h Volume:
8.07M
Relative Volume:
1.27
Market Cap:
$390.40B
Revenue:
$61.16B
Net Income/Loss:
$4.20B
P/E Ratio:
93.32
EPS:
2.3671
Net Cash Flow:
$19.68B
1W Performance:
+1.74%
1M Performance:
+0.37%
6M Performance:
+11.20%
1Y Performance:
+15.15%
1-Day Range:
$218.05
$224.15
1-Week Range:
$214.04
$225.82
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
220.89 | 393.14B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
LLY
Lilly Eli Co
|
1,015.21 | 917.39B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
240.86 | 574.26B | 94.19B | 26.80B | 20.46B | 11.05 |
|
AZN
Astrazeneca Plc
|
204.76 | 299.82B | 58.07B | 9.40B | 9.87B | 3.0115 |
|
NVS
Novartis Ag Adr
|
160.06 | 301.87B | 54.72B | 14.02B | 15.32B | 7.1855 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie Sues Medicaid, HHS Over Botox Fair Price Controls - Law360
Evercore ISI Cuts AbbVie Inc. (ABBV) PT, Says Consensus for 2026 and 2027 Still Looks Beatable - Insider Monkey
Evercore ISI cuts AbbVie Inc. (ABBV) PT, says consensus for 2026 and 2027 still looks beatable - MSN
Abbvie sues US health agency over Botox - 1470 & 100.3 WMBD
AbbVie sues US health agency over Botox price controls - Yahoo Finance
AbbVie Sues HHS Over Selection of Botox for Medicare Price Cuts - Bloomberg Law News
AbbVie sues US health agency over Botox - marketscreener.com
AbbVie sues U.S. Department of Health and Human Services over selection of Botox for IRA Medicare drug negotiations - marketscreener.com
AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch - TipRanks
P/E Ratio Insights for AbbVie - Benzinga
The 5 Most Interesting Analyst Questions From AbbVie's Q4 Earnings Call - Finviz
Rhumbline Advisers Trims Stock Position in AbbVie Inc. $ABBV - MarketBeat
Krilogy Financial LLC Raises Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Stratos Wealth Partners LTD. Has $41.28 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Cibc World Market Inc. Acquires 60,635 Shares of AbbVie Inc. $ABBV - MarketBeat
58,432 Shares in AbbVie Inc. $ABBV Purchased by Caprock Group LLC - MarketBeat
ING Groep NV Purchases 528,196 Shares of AbbVie Inc. $ABBV - MarketBeat
Hepatitis B Treatment Market Size is Projected to Reach USD 7.74 Billion by 2033 Due to the Increasing Disease Management Trends Globally - GlobeNewswire Inc.
AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data - TechStock²
AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals - Yahoo Finance
Here's What Will Drive AbbVie's Top-line Growth in 2026 - The Globe and Mail
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Wealthfront Advisers LLC Has $40.61 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by SVB Wealth LLC - MarketBeat
The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call - The Globe and Mail
AbbVie's Botox For Chronic Migraine Leads Pharma SB Program Advertisers 02/10/2026 - MediaPost
The Truth About AbbVie Inc.: Why Everyone Is Suddenly Watching This Pharma Giant - AD HOC NEWS
AbbVie, Astra Lose Appeal Over Louisiana Contract Pharmacy Law - Bloomberg Law News
Is Abbvie Stock Overvalued in 2026 After a 15% Rally Last Year? - TIKR.com
AbbVie Insiders Sell US$41m Of Stock, Possibly Signalling Caution - 富途牛牛
BNP Paribas Exane Adjusts Price Target on AbbVie to $213 From $203, Maintains Neutral Rating - marketscreener.com
Candriam S.C.A. Has $193.50 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
ProShare Advisors LLC Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
Oppenheimer Asset Management Inc. Acquires 4,730 Shares of AbbVie Inc. $ABBV - MarketBeat
Legacy Financial Strategies LLC Sells 12,664 Shares of AbbVie Inc. $ABBV - MarketBeat
Oppenheimer & Co. Inc. Acquires 5,688 Shares of AbbVie Inc. $ABBV - MarketBeat
DOJ Drops Challenge To AbbVie's $1.6B Break Fee Deduction - Law360
AbbVie stock price closes higher on Moody’s upgrade — what ABBV bulls and bears watch next - TechStock²
Insiders At AbbVie Sold US$41m In Stock, Alluding To Potential Weakness - Yahoo Finance
Smartleaf Asset Management LLC Raises Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Alps Advisors Inc. - MarketBeat
Lupin and AbbVie Announce Partnership to Develop and Commercialize Novel Oncology Drug to treat Hematological CancersLupin | Press Release - lupin.com
Top Picks 2026: AbbVie Inc. - Longbridge
Earnings Scorecard: 22 out of 23 healthcare firms deliver EPS wins this week - Seeking Alpha
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next - TechStock²
AbbVie (ABBV) Receives a Buy from Guggenheim - The Globe and Mail
Garland Capital Management Inc. Lowers Stake in AbbVie Inc. $ABBV - MarketBeat
Renaissance Group LLC Has $36.57 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Canada Post Corp Registered Pension Plan Has $11.50 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Position Decreased by Twin Capital Management Inc. - MarketBeat
AbbVie (NYSE:ABBV) Trading 2% Higher Following Analyst Upgrade - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.87%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):